About ProZyme
ProZyme is a company based in Hayward (United States) founded in 1990 was acquired by Agilent in June 2018. ProZyme operates in a competitive market with competitors including GlyTech, Echelon Biosciences, Iceni Glycoscience, GlycoSpot and Avanti Polar Lipids, among others.
Apps and channels of ProZyme
its YouTube channel Agilent Technologies has 42K subscribers and 30 videos.
Videos from ProZyme
The most watched videos on ProZyme's YouTube channel, Agilent Technologies (42K subscribers). Click a video to play it here.
More on Agilent Technologies.
Funding Insights of ProZyme
- Total Rounds 1
- Last Round Debt – Conventional — $321,414
- First Round $321,414
(Oct 2011)
All 1 funding rounds of ProZyme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2011 | $321,414 | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in ProZyme
ProZyme has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Agilent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified instruments are developed for scientific and laboratory management. | 1995 | agilent.com | Santa Clara, United States |
Investor details for ProZyme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ProZyme
1 people are tracked at ProZyme (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sergey Vlasenko | CEO & President | Leadership |
Complete people profiles for ProZyme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ProZyme
3 dated milestones of ProZyme across 28 years, from founding to its latest funding, stage changes and deals.
- Founded ProZyme is founded.
- Funding First funding round of $321K.
- Exit Acquired by Agilent.
Competitors of ProZyme
ProZyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GlyTech, Echelon Biosciences, Iceni Glycoscience, GlycoSpot and Avanti Polar Lipids, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| glytech-inc.com | 2012 | Kyoto, Japan | $9.14M | – | Human-type Asp-linked glycans are supplied for research applications. | |
| echelon-inc.com | 1997 | Salt Lake, United States | – | – | Reagents and assays for lipid biology research are manufactured. | |
| iceniglycoscience.com | 2014 | Norwich, United Kingdom | $1.77M | 16 | Glycoscience platform is provided for diagnostic and therapeutic applications. | |
| glycospot.dk | 2014 | Frederiksberg, Denmark | $3.58M | 13 | High-throughput enzyme screening solutions are developed and provided. | |
| avantilipids.com | 1969 | Alabaster, United States | – | 134 | Phospholipids and lipids are manufactured for life science applications. | |
| tfchemistry.com | 2007 | Rouen, France | – | – | Fluoride chemistry is utilized to design glycomimetic drug compounds. | |
| addaxbio.com | 2017 | Turin, Italy | – | – | Developer of a non-toxic formalin alternative tissue fixative. This fixative provides comparable or superior results to formalin in histological, immunohistochemical, and molecular analyses, while eliminating the carcinogenic and toxic risks associated with formalin use. The product is protected by an international patent and is designed for use in histology laboratories, improving both patient care and worker safety. The company collaborates with various research institutions to advance the application of this technology in different fields. | |
| glycot.com | 2015 | Ellicott, United States | – | 5 | Proprietary glycoengineering technologies for therapeutic antibodies are developed. |
Detailed competitors of ProZyme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ProZyme
Websites that share an audience with ProZyme (prozyme.com).
Websites whose visitors overlap most with ProZyme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vectorlabs.com | 100% | 65.9K | #500,436 | View details | |
| invitrogen.com | 86% | 5.2K | #3,688,642 | View details | |
| biomol.com | 82% | 92.2K | #441,145 | View details | |
| chondrex.com | 82% | 19.4K | #1,254,033 | View details | |
| mpbio.com | 82% | 112.2K | #351,727 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for ProZyme
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Prozyme
Complete news archive for ProZyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ProZyme
10 companies that operate in the same segment as ProZyme (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ProZyme
ProZyme was founded in 1990 and raised its 1st funding round 21 years after it was founded.
ProZyme is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Sergey Vlasenko is the current CEO of ProZyme.
Founded in 1990 and based in Hayward, United States, ProZyme operates in the glycosciences sector. Biochemical reagents and supplies for carbohydrate analysis are developed, manufactured, and commercialized. Tools such as GlykoScreen and GlykoPrep for glycobiology are offered, along with PhycoLink conjugates, activated phycobiliproteins, and streptavidin-related products. Services for N-Glycan screening, identification, and characterization are also provided.
ProZyme's top competitors include GlyTech, Echelon Biosciences and Iceni Glycoscience.
ProZyme has 1 investor. Key investors include Agilent.
Yes. ProZyme was acquired by Agilent in June 2018.